Abstract:Machine learning methods offer time- and cost-effective means for identifying novel chemical matter as well as guiding experimental efforts to map enormous compound-kinase interaction spaces. However, considerable challenges for compound-kinase interaction modeling arise from the heterogeneity of available bioactivity readouts, including single-dose compound profiling results, such as percentage inhibition, and multi-dose-response results, such as IC . Standard activity prediction approaches utilize only dose-response data in the model training, disregarding a substantial portion of available information contained in single-dose measurements. Here, we propose a novel machine learning methodology for compound-kinase activity prediction that leverages both single-dose and dose-response data. Our two-stage model first learns a mapping between single-dose and dose-response bioactivity readouts, and then generates proxy dose-response activity labels for compounds that have only been tested in single-dose assays. The predictions from the first-stage model are then integrated with experimentally measured dose-response activities to model compound-kinase binding based on chemical structures and kinase features. We demonstrate that our two-stage approach yields accurate activity predictions and significantly improves model performance compared to training solely on dose-response labels, particularly in the most practical and challenging scenarios of predicting activities for new compounds and new compound scaffolds. This superior performance is consistent across five evaluated machine learning methods, including traditional models such as random forest and kernel learning, as well as deep learning-based approaches. Using the best performing model, we carried out extensive experimental profiling on a total of 347 selected compound-kinase pairs, achieving a high hit rate of 40% and a negative predictive value of 78%. We show that these rates can be improved further by incorporating model uncertainty estimates into the compound selection process. By integrating multiple activity data types, we demonstrate that our approach holds promise for facilitating the development of training activity datasets in a more efficient and cost-effective way.

Optimization of a Multi-Feature AI Ensemble and Voting System for MAPKAPK2 Inhibitor Discovery

MinKLIFSAI: a simple machine learning approach toward selective kinase inhibitor

Exploration and Augmentation of Pharmacological Space Via Adversarial Auto-Encoder Model for Facilitating Kinase-Centric Drug Development

Establishment of extensive artificial intelligence models for kinase inhibitor prediction: Identification of novel PDGFRB inhibitors

Large-scale comparison of machine learning methods for profiling prediction of kinase inhibitors

Kinome-Wide Virtual Screening by Multi-Task Deep Learning

An ensemble machine learning model generates a focused screening library for the identification of CDK8 inhibitors

Teaching old docks new tricks with machine learning enhanced ensemble docking

Leveraging Machine Learning and AlphaFold2 Steering to Discover State-Specific Inhibitors Across the Kinome

The Development and Application of KinomePro-DL: A Deep Learning Based Online Small Molecule Kinome Selectivity Profiling Prediction Platform

SAE-SV: A Stacked-AutoEncoder and Soft Voting Joint Approach Based on Small Dataset with High Dimensions for Inhibitory Potency Prediction

Docking-informed machine learning for kinome wide affinity prediction

Knowledge-Based Methods To Train and Optimize Virtual Screening Ensembles

Investigation of dual JAK2 and HDAC6 inhibitors using machine learning methods

Leveraging multiple data types for improved compound-kinase bioactivity prediction

Crowdsourced mapping of unexplored target space of kinase inhibitors

Virtual Screening of Pharmaceutical Compounds with hERG Inhibitory Activity (Cardiotoxicity) using Ensemble Learning

Machine Learning-Enabled Pipeline for Large-Scale Virtual Drug Screening

A Hybrid Structure-Based Machine Learning Approach for Predicting Kinase Inhibition by Small Molecules

Consensus holistic virtual screening for drug discovery: a novel machine learning model approach

Constructing and Validating High-Performance MIEC-SVM Models in Virtual Screening for Kinases: A Better Way for Actives Discovery.